Excellent -- and here's a bit of it:
. . .Leading HIV treatment developer Gilead’s scientists spent 20 years developing lenacapavir, an antiviral drug that targets a specific protein on the virus’ shell. Vaccines have similarly targeted other outer viral proteins, and the idea is that priming the immune system to recognize this part of HIV can help it to generate defenses against the virus if someone is later exposed. Lenacapavir was already approved to treat HIV, and in June the FDA also approved it as a preventive therapy. Widespread use of the medication could bring the world closer to ending the HIV epidemic.
The company’s CEO Dan O’Day says Gilead is equally committed to ensuring that those who are at highest risk of getting infected with HIV have access to the drug. He signed a voluntary licensing agreement in 2024 that allows half a dozen generic manu- facturers to make lenacapavir for 120 low and middle income countries, where HIV remains a significant threat.
Close to 40 million people have HIV or AIDS globally, but a disproportionate number -- about two-thirds -- live in subsaharan Africa. “Not that many companies focus on virology,” he says. “And if we are going to produce a drug, and put our blood, sweat and tears into it, then it’s got to end up in everybody’s hands who can use it. . . .”
Pride Run '25 in the books, already. Done, and done! Onward.
नमस्ते
No comments:
Post a Comment